CMO Tecomet buys Teleflex's ortho unit; Paraxel inks deal with the Korea Drug Development Fund;

 @DamianFierce: A new study says low-income patients are less likely to join cancer trials, raising questions of access and education. More | Follow @DamianFierce

> CMO Tecomet is paying $45.2 million for devicemaker Teleflex's orthopedics unit, a business that pulled in about $36 million last year. News

> Paraxel has signed on with the Korea Drug Development Fund, an outfit worth about $1 billion, to help researchers in that country develop and commercialize new treatments. More

> Battelle has secured a 10-year research contract worth up to $102.5 million from the National Institutes of Health, tasked with carrying out clinical tests of vaccines and biologics designed to halt infectious disease. Article  

> Clinipace is working with Prometheus Laboratories to run trials of Proleukin, the company's candidate melanoma treatment. Item

> PPD continues its managerial shake-up, appointing former Roche exec Louis Renzetti as vice president of strategic laboratory operations. Release

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.